Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions

Fig. 3

Comparison of prognosis to EGFR-TKIs in NSCLC patients with different types of EGFR 19ins. A Kaplan–Meier curve comparing progression-free survival of NSCLC patients with EGFR 19ins and EGFR 19del [21] receiving first-line EGFR-TKI treatment. B Kaplan–Meier curve comparing progression-free survival of two EGFR 19ins subtypes after first-line EGFR-TKI treatment. C Swimming plot illustrating treatment history of 17 EGFR 19ins patients. D Kaplan–Meier curve comparing progression-free survival of different EGFR-TKIs in EGFR 19ins patients. E Kaplan–Meier curve comparing progression-free survival of gefitinib versus other two first-generation EGFR-TKIs (erlotinib and icotinib) in our cohort. F Kaplan–Meier curve comparing progression-free survival of gefitinib versus other two first-generation EGFR-TKIs (erlotinib and icotinib) in previous studies. G Kaplan–Meier curve comparing progression-free survival of EGFR 19ins or EGFR 19del patients treated with osimertinib [22]

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us